PET, MRI and ultrasound to track heart changes in ATTR cardiac amyloidosis
Official title: Natural History of Cardiac Transthyretin Amyloidosis - Mechanistic Insights by Multimodality Imaging
Run by University of Zurich · NCT07112066 · Data updated 2026-11-12
This study will try PET, MRI and ultrasound scans in people with ATTR cardiac amyloidosis starting tafamidis to see if the new images explain why some patients keep getting worse.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University of Zurich Academic / other |
| Locations | 1 site (Zurich, Canton of Zurich) |
| Status | Recruiting |
| Started | October 20, 2025 |
| Main results expected | June 2027 |
| Study ends | June 2027 |
| Registry record updated | December 9, 2025 |
| Trial ID | NCT07112066 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with confirmed cardiac ATTR amyloidosis who are about to start tafamidis at the University Hospital Zurich and meet the study exclusion criteria.
✕Probably not a fit
Patients already receiving other disease-modifying therapies, those with ongoing supraventricular arrhythmia, ventricular pacing, prior septal myocardial infarction, or those unable to attend baseline and 12‑month imaging are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This open-label, prospective longitudinal study will enroll 50 people with cardiac ATTR amyloidosis who are about to start tafamidis and perform serial imaging at baseline and after 12 months. Participants will have cardiac ultrasound, cardiac MRI, and cardiac PET with an 18F-FAPI tracer, along with blood tests (including NT-proBNP, troponin and BMP4) and functional assessments (NYHA class, KCCQ, 6‑minute walk). Conventional clinical, laboratory and imaging markers will be collected during routine follow-up to classify progression (expected in ~30%) and to compare with novel imaging signals. Patients on other disease-modifying therapies or with ongoing supraventricular arrhythmia, ventricular pacing, or prior septal myocardial infarction are excluded.
Why it matters
Potential benefit: If successful, the approach could identify imaging or blood markers that detect early progression and help personalize treatment for people with ATTR cardiac amyloidosis.
How similar studies have gone: While MRI and conventional echocardiography are established in ATTR, use of 18F-FAPI PET and serum BMP4 for tracking disease progression is novel and has limited prior clinical validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants with cardiac ATTR amyloidosis, as recently defined by multi-societal criteria, who are about to start tafamidis at the University Hospital Zurich Exclusion Criteria: * Any other disease-modifying therapy (e.g. patisiran) * Ongoing supraventricular arrhythmia * Ventricular pacing * Prior septal myocardial infarction
Where it's running
-
University Hospital Zurich
Zurich, Canton of Zurich, Switzerland Recruiting
Study contacts
- Principal investigator: Dominik C Benz, MD — Universität Zürich
- Study coordinator: Dominik C Benz, PD Dr. med.
- Email: dominik.benz@usz.ch
- Phone: +41432531191
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Detecting cardiac amyloidosis in people with severe aortic valve narrowing
This study tests non-invasively whether imaging tests can find heart amyloidosis in patients with severe aortic stenosis who are being evaluated for valve replacement.
-
Multimodal analysis of heart biopsy samples
This project will take one extra small heart biopsy during a clinically needed procedure to test whether detailed molecular and immune analyses can find disease-specific signatures in adults with cardiomyopathies, myocarditis, cardiac amyloidosis, or after heart transplant.
-
Using tiny blood particles to detect and track ATTR heart amyloidosis
This project will test whether tiny blood particles called extracellular vesicles can help detect and track transthyretin (ATTR) amyloid cardiomyopathy in people with or at risk for ATTR.
-
Belgian Amyloidosis Biobank and Patient Registry at UZ Leuven
This project collects and stores blood, tissue samples, and medical data from adults with suspected or confirmed amyloidosis to create a biobank and registry for future research.
-
Registry for patients with systemic amyloidosis
This study is collecting information from patients with systemic amyloidosis to better understand the disease and how different treatments work over time.
-
Identifying patients with cardiomyopathy for potential heart transplantation
This study is trying to find new ways to identify and understand cardiomyopathy in patients to better predict if they might need a heart transplant in the future.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.